AI Medical Compendium Topic

Explore the latest research on artificial intelligence and machine learning in medicine.

Crohn Disease

Showing 61 to 70 of 72 articles

Clear Filters

Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
BACKGROUND: The use of therapeutic drug monitoring has been proposed as a useful tool in the management of patients with loss of response to biological therapy in patients with inflammatory bowel disease.

Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease.

Inflammatory bowel diseases
BACKGROUND: In a pilot study, neutrophil CD64 surface expression was significantly elevated in newly diagnosed, pediatric-onset Crohn's disease. We aimed to test the CD64 biomarkers (neutrophil CD64 surface expression and soluble CD64) as determinate...

Bayesian Machine Learning Techniques for revealing complex interactions among genetic and clinical factors in association with extra-intestinal Manifestations in IBD patients.

AMIA ... Annual Symposium proceedings. AMIA Symposium
The objective of the study is to assess the predictive performance of three different techniques as classifiers for extra-intestinal manifestations in 152 patients with Crohn's disease. Naïve Bayes, Bayesian Additive Regression Trees and Bayesian Net...

Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.

International journal of clinical and experimental pathology
Interleukin-33 (IL-33) is a cytokine that belongs to the interleukin-1 family and has been shown to be associated with mucosal inflammation. The aim of this study was to determine the serum level of IL-33 in children with ulcerative colitis (UC) and ...

LOWER LEVELS OF VITAMIN D CORRELATE WITH CLINICAL DISEASE ACTIVITY AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE.

Arquivos de gastroenterologia
BACKGROUND: Inflammatory bowel disease, comprising Crohn's disease and ulcerative colitis, is a group of debilitating conditions associated with deregulated mucosal immune response. Vitamin D has been implicated in immune response and gastrointestina...

Vitamin D status in relation to Crohn's disease: Meta-analysis of observational studies.

Nutrition (Burbank, Los Angeles County, Calif.)
OBJECTIVES: Inconsistent findings have been published regarding vitamin D status among patients with Crohn's disease (CD) and the association with disease severity. We aimed to perform a meta-analysis evaluating serum 25-hydroxy vitamin D and 1,25 de...

Effect of fuzzy partitioning in Crohn's disease classification: a neuro-fuzzy-based approach.

Medical & biological engineering & computing
Crohn's disease (CD) diagnosis is a tremendously serious health problem due to its ultimately effect on the gastrointestinal tract that leads to the need of complex medical assistance. In this study, the backpropagation neural network fuzzy classifie...

An empirical fuzzy multifactor dimensionality reduction method for detecting gene-gene interactions.

BMC genomics
BACKGROUND: Detection of gene-gene interaction (GGI) is a key challenge towards solving the problem of missing heritability in genetics. The multifactor dimensionality reduction (MDR) method has been widely studied for detecting GGIs. MDR reduces the...

A probabilistic pathway score (PROPS) for classification with applications to inflammatory bowel disease.

Bioinformatics (Oxford, England)
SUMMARY: Gene-based supervised machine learning classification models have been widely used to differentiate disease states, predict disease progression and determine effective treatment options. However, many of these classifiers are sensitive to no...

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.

Inflammatory bowel diseases
BACKGROUND AND AIMS: Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers.